Related references
Note: Only part of the references are listed.Priorities for global health community in COVID-19 pandemic
Lidia Rudnicka et al.
DERMATOLOGIC THERAPY (2020)
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Philippe Gautret et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta et al.
LANCET (2020)
The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease
Dennis McGonagle et al.
AUTOIMMUNITY REVIEWS (2020)
Anti-Inflammatory Properties of Low and High Doxycycline Doses: An In Vitro Study
Roberta Di Caprio et al.
MEDIATORS OF INFLAMMATION (2015)
Abnormal Weight Gain and Gut Microbiota Modifications Are Side Effects of Long-Term Doxycycline and Hydroxychloroquine Treatment (Publication with Expression of Concern. See vol. 66, 2022)
Emmanouil Angelakis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Share Paper
